The concern of generic porn rivalry has consistently loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of related medicinal portfolios. While early periods saw impressive returns, the exclusivity lapse has opened the way for less expensive copies, potentially lowering revenue and posing a genuine risk